Status:
NOT_YET_RECRUITING
A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).
Lead Sponsor:
NovoBliss Research Pvt Ltd
Collaborating Sponsors:
Zywie Ventures Privated Ltd
Conditions:
Androgenic Alopecia
Eligibility:
All Genders
25-45 years
Phase:
NA
Brief Summary
This is a prospective, interventional, exploratory, four-arm - dose response study, comparative, double-blind, randomized, placebo-control, proof of concept, safety, efficacy and in-use tolerability s...
Detailed Description
A total of up to 72 patients (18 patients/arm) preferably equal number of male and female will be enrolled to ensure a total of 60 patients (15 patients/ arm) to complete the study. There will be tot...
Eligibility Criteria
Inclusion
- Age: 25 to 45 years and above (both inclusive) at the time of consent.
- Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- Females of childbearing potential must have a self-reported negative urine pregnancy.
- Patient is in good general health as determined by the Investigator on the basis of medical history.
- Patients having mild to moderate Androgenic Alopecia (Grade I to III) during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification and Ludwig pattern scale for female.
- Female with 40-50 counts and male with 25 -30 counts of hair fall at screening.
- Patient is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- If the patient is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- Patients are willing to give written informed consent and are willing to follow the study procedure.
- Patients who commit not to use any other medicated/ prescription shampoos/hair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study.
- Willing to consume test products throughout the study period.
- Patient is willing and able to follow and allow study staff to performed study test methods.
- Patient is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- Patient must be able to understand and provide written informed consent to participate in the study.
Exclusion
- Patient have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.
- Patient have history of any dermatological condition of the scalp other than hair loss and dandruff.
- Patient have history of any prior hair growth procedures (e.g. hair transplant or laser).
- Patient who had taken topical treatment of hair loss for at least 4 weeks.
- Patient who had taken any systemic treatment for at least 3 months.
- History of alcohol or drug addiction.
- Patient having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease.
- Patient who is currently participating in or planning on starting weight loss program that may result in a significant change in overall body weight.
- Pregnant or breast feeding or planning to become pregnant during the study period.
- History of chronic illness which may influence the cutaneous state.
- Patient have participated any clinical research study related to hair care products.
- Patient have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
Key Trial Info
Start Date :
August 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 2 2025
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06551818
Start Date
August 30 2024
End Date
March 2 2025
Last Update
August 13 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.